🇺🇸 FDA
Pipeline program

Lucinactant for Inhalation

03-CL-1702

Phase 2 other terminated

Quick answer

Lucinactant for Inhalation for Respiratory Distress Syndrome, Newborn is a Phase 2 program (other) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).

Program details

Company
WINDTREE THERAPEUTICS INC /DE/
Indication
Respiratory Distress Syndrome, Newborn
Phase
Phase 2
Modality
other
Status
terminated

Clinical trials